Veteran Analyst Revamps Pfizer Stock Price Target for Rest of 2026
Pfizer (PFE) received an RBC Capital Markets rating upgrade to Sector Perform from Underperform after the stock pulled back from its 2026 high, according to RBC. Analyst Trung Huynh kept a $25 price target, noting PFE trades near a one-year forward P/E of 9 and citing a 7% dividend yield. RBC pointed to mid-2026 lung cancer and second-half 2026 prostate cancer readouts as potential 2026 catalysts.
How this was made
The 30-second read
Why it matters
The note ties the valuation case (near 9x forward P/E) and dividend yield to two late-stage oncology readouts expected in mid-2026 and 2H-2026, implying potential 2026 outlook lift.
Market read
A current analyst upgrade with a reiterated target can drive incremental flows, while the real fundamental inflection depends on upcoming clinical readouts.
What to watch
Forward P/E near 9x and a $25 target can already be partially priced; traders may discount the catalysts until actual readout details (endpoints, response rates) are released.
Background
RBC moved Pfizer from Underperform to Sector Perform after the stock pulled back from its 2026 high, arguing risk-reward improved.
Ticker impact
RBC upgraded Pfizer to Sector Perform and kept a $25 target, citing a more even risk-reward after the stock’s pullback.
Bias modestly positive over days/weeks, with follow-through risk if the cited late-stage readouts disappoint or timing slips.
The article’s actionable catalyst is an upgrade/target update, while the clinical readout timing is forward-looking and not yet confirmed by new trial results.
Market effects
Supports a broader “value + pipeline catalysts” read-through for large-cap pharma, but without new trial data it’s more sentiment than fundamentals.
Primarily US large-cap pharma sentiment; limited direct regional spillover beyond healthcare allocators.
Oncology pipeline timing may influence global pharma risk appetite, though the article provides no new global regulatory or trial outcome.
Counterpoint
The upgrade is based on valuation/risk-reward and dividend support, not new efficacy/safety data; upside may fade if catalysts are delayed or underwhelm.
Key entities
- companyPfizer
Drugmaker receiving an RBC rating upgrade and reiterated $25 price target; catalysts cited for 2026 oncology programs.
- analyst_firmRBC Capital Markets
Issued the upgrade and valuation framing; highlighted dividend support and two late-stage readouts.
- drug_candidatesigvotatug vedotin
Lung cancer late-stage readout expected mid-2026 per the article.
- drug_candidatemevrometostat
Prostate cancer late-stage readout expected in the second half of 2026 per the article.
